An analysis of subgroups revealed that the PD-1/PD-L1 inhibitor did not improve the rate of overall survival in patients with PD-L1-expressing immune cells on ≥5% of the tumor area (IC2/3 per immunohistochemistry assay), compared with chemotherapy alone (HR, 0.84; 95% CI, 0.70–1.00; p = 0.04) (Figure 3A). The gene discussed is CD274; the disease is neoplasm.